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ABSTRACT
Aprataxin, defective in the neurodegenerative
disorder ataxia oculomotor apraxia type 1, resolves
abortive DNA ligation intermediates during DNA
repair. Here, we demonstrate that aprataxin local-
izes at sites of DNA damage induced by high LET
radiation and binds to mediator of DNA-damage
checkpoint protein 1 (MDC1/NFBD1) through a
phosphorylation-dependent interaction. This inter-
action is mediated via the aprataxin FHA domain
and multiple casein kinase 2 di-phosphorylated
S-D-T-D motifs in MDC1. X-ray structural and
mutagenic analysis of aprataxin FHA domain,
combined with modelling of the pSDpTD peptide
interaction suggest an unusual FHA binding mecha-
nism mediated by a cluster of basic residues at and
around the canonical pT-docking site. Mutation of
aprataxin FHA Arg29 prevented its interaction with
MDC1 and recruitment to sites of DNA damage.
These results indicate that aprataxin is involved not
only in single strand break repair but also in the pro-
cessing of a subset of double strand breaks presum-
ably through its interaction with MDC1.
INTRODUCTION
Aprataxin, defective in the human autosomal recessive
disorder ataxia oculomotor apraxia type 1 (AOA1),
is encoded by the APTX gene (1,2). AOA1 is a neuro-
degenerative disorder characterized by early onset
cerebellar ataxia, oculomotor apraxia, hypoalbuminemia
and late peripheral neuropathy (3). It resembles ataxia
telangiectasia (A-T) in its neurodegenerative phenotype
but lacks the extra-neurological features of A-T that
include radiosensitivity, immunodeﬁciency and cancer
predisposition (3,4). ATM, the protein defective in A-T,
recognizes and is activated by DNA double strand breaks
(DSB) to signal this damage to the DNA repair machinery
and activate cell cycle checkpoints (5).
Aprataxin contains three functional domains: an
N-terminal FHA domain (6), a central histidine triad
(HIT) domain (7) and a C-terminal zinc ﬁnger motif.
Aprataxin interacts with XRCC1 and PARP-1, two key
components of the DNA base excision repair machinery
(8–10), suggesting a role for aprataxin in DNA single
strand break (SSB) repair. Cells derived from AOA1
patients are sensitive to genotoxic agents that induce
SSB in DNA (8–12). Consistent with the involvement of
aprataxin in DNA repair, defective SSB repair has been
reported in AOA1 cells in response to camptothecin, H2O2
and BSO (11–13). More recently aprataxin was shown to
catalyze the nucleophilic release of adenylate groups
covalently linked to 50-termini of DNA molecules
(14,15). Ligation of SSB or DSB involves the formation
of an AMP-ligase complex, which subsequently transfers
the AMP moiety onto the 50 phosphate of the break site
from which it is released after the formation of the
phosphodiester bond (16). The AMP hydrolase activity
of aprataxin appears to be important in resolving
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abortive DNA ligation intermediates that can form at
‘dirty’ or ‘complex’ SSB and potentially also at DSB
formed by reactive oxygen species attack or clustered
damage (15). The involvement of aprataxin in DNA
repair is further supported by recent evidence of elevated
levels of oxidative DNA damage in AOA1 cells coupled
with a reduced expression of PARP-1, apurinic endo-
nuclease 1 (APE1) and OGG1 (17). Furthermore,
impaired base excision and gap ﬁlling repair eﬃciencies
reveals a synergy between aprataxin, PARP-1, APE-1
and OGG1 in the DNA damage response and highlights
both direct and indirect modulating functions for
aprataxin on base excision repair (17). Although a role
for aprataxin in the repair of abortive ligations at sites
of DSB has been suggested by the interaction between
aprataxin and XRCC4 (9) and the in vitro binding of
aprataxin to DNA double strand ends (15,18), no direct
evidence for its involvement in DNA double strand break
repair has been reported (19).
In response to DNA damage, many proteins involved in
DNA damage signalling/repair, such as Mre11, NBS1 and
53BP1 quickly re-localize to nuclear foci (20,21). These
foci co-localize with the phosphorylated form of histone
H2AX (gH2AX), a well-established marker for DSB (22).
While aprataxin interacts with XRCC1, XRCC4 and
PARP-1, we have previously shown that in contrast to
the other DNA repair proteins, it does not form detectable
nuclear foci after DNA damage exposure induced by
either low linear energy transfer (LET) ionizing radiation
(IR) or H2O2 (8). The dynamics of recruitment of DNA
repair proteins to sites of DNA damage has been
investigated by laser irradiation combined with photo-
sensitizers (23–25). Hirano et al. (2007) employed this
approach to show that aprataxin was recruited in vivo to
SSB. While laser-induced DNA damage produces SSB
and DSB, the relative distribution and the density of the
damage are greatly inﬂuenced by the laser type, energy
output and the type of photosensitizer (26). Biological
imaging of charged particle tracks represents an alterna-
tive approach for investigating the association of repair
proteins with chromatin (27,28). This technology oﬀers
the advantage of deﬁned intrinsic physical properties of
the heavy ion beams and allows the density of lesions
along the track to be varied with ion species with diﬀerent
LET values. Using a remote-controlled microscope
coupled to the beamline that allows the acquisition of
ﬂuorescence images of living cells, in real-time during
ion irradiation, we observed that GFP-aprataxin is
rapidly localized to DNA damage induced by nickel-ion-
irradiation (8,28). To gain further insight how aprataxin
is recruited to sites of DNA breaks, we investigated the
in vivo recruitment of GFP-tagged aprataxin to localized
DNA damage induced by high LET heavy ion irradia-
tion. We demonstrate for the ﬁrst time that aprataxin
co-localizes and interacts with mediator of DNA
damage checkpoint protein 1 (MDC1), a protein that
ampliﬁes ATM-dependent DNA damage signalling
(29–35). Interaction between the two proteins is
mediated through the FHA domain of aprataxin, which
binds to a casein kinase II (CK2)-phosphorylated
N-terminal region of MDC1. Mutation of aprataxin
Arg29, a key residue conserved within FHA motifs (36),
disrupted the interaction between aprataxin and MDC1,
and abolished its recruitment to sites of DNA damage.
These results together with those of Harris et al. (17) high-
light the importance of the aprataxin FHA domain in
regulating protein–protein interactions and targeting
aprataxin to sites of DNA damage.
MATERIALS AND METHODS
Cell lines, inhibitors
Control lymphoblastoid cell line (LCL) (C3ABR) and
cervical adenocarcinoma cells (HeLa) were cultured
in RPMI 1640 (GIBCO BRL) and DMEM (GIBCO
BRL), respectively containing 10% foetal calf serum
(FCS) (Lonza), 2mM L-glutamine (Life Technologies),
100U/ml penicillin (GIBCO BRL), 100U/ml streptomy-
cin (GIBCO BRL) and maintained in a humidiﬁed
incubator at 37C/5% CO2. Wild type, Aptx
/ and
Mdc1/ mouse embryonic ﬁbroblasts (MEF), and
human AOA1 ﬁbroblasts (FD105) hTERT-transformed
(Gift from Prof. Keith Caldecott, University of Sussex,
UK) were cultured in DMEM as described earlier.
CK2 inhibitors 4,5,6,7-tetrabromotriazole (TBB), and
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole
(DMAT) were purchased from Calbiochem and dissolved
in DMSO.
Aprataxin-GST and MDC1-GST pull down assays
Aprataxin-GST proteins have been described earlier
(8,37). Pull down assays, were performed as described
in Supplementry Data. Proteins were separated on 5%
and 10% SDS–PAGE, transferred onto nitrocellulose
membranes (Hybond C, Amersham) and detected using
the relevant antibody. Aprataxin antibodies have been
described earlier (8,37). Sheep polyclonal MDC1
antibody was produced against GST-MDC1 fragments
and puriﬁed by aﬃnity column against GST only and
the antigen using standard protocols. For immuno-
blotting, antibodies were used at dilutions of: MDC1
(1/2000), aprataxin (1/2000), anti-GST (1/2000) followed
by the relevant species-speciﬁc HRP-conjugated secondary
antibody from Chemicon or Sigma (1/10 000).
In vivo CK2 inhibition and pull downs
HeLa cells were mock treated (DMSO) or treated with a
range of concentrations of speciﬁc CK2 inhibitor TBB,
or DMAT for 8 h in a six well-plate format and then
lysed. Pull down was performed as described in
Supplementary Data.
In vitro CK2 phosphorylation and pull down
A region of MDC1 containing CK2 sites (amino acids
150–350) was cloned into the bacterial GST expression
vector pGEX-6P-1, expressed in E. coli (BL21DE3) and
puriﬁed as described by the manufacturer. Two micro-
grams of each GST fusion protein was in vitro phos-
phorylated by incubation with 200 ng of human
recombinant CK2 (New England Biolabs) in buﬀer P
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(20mM Tris–HCl pH 7.5, 50mM KCl, 10mM MgCl2,
200 mM ATP) for 1 h at 37C. Once phosphorylated,
GST fusion proteins were used in pull-down assays
mixed with 2mg of HeLa whole cell extracts (WCE) as
described earlier.
Immunoprecipitation and immunoblotting
Total cell extracts from control (C3ABR) cells were
prepared as described in Supplementary Data and the
equivalent of 1mg of total protein was immunopre-
cipitated with non-speciﬁc serum (1 or 5 mg), aprataxin
(1 mg) and MDC1 (5mg) antibodies overnight at 4C.
40 ml of protein G-Sepharose beads (Amersham) were
added to the immunoprecipitation (IP) and incubated
for 1 h on a rotating wheel at 4C. IP were washed three
times with lysis buﬀer and the beads were resuspended in
20 ml of sample loading buﬀer. Proteins were separated on
5% and 10% SDSPAGE, transferred onto nitrocellulose
membranes and detected using the relevant primary and
secondary antibodies.
Isothermal titration calorimetry
Phosphopeptides were synthesised by Dr W. Mawby
(University of Bristol). Aprataxin FHA-phosphopeptide
binding was quantiﬁed by isothermal titration calorimetry
(ITC) using a Microcal Omega VP-ITC calorimeter
(MicroCal Inc., Northampton, MA, USA). Protein was
dialysed against ITC buﬀer (50mM HEPES pH 7.5,
150mM NaCl, 5mM b-mercaptoethanol) and peptides
were dissolved in the dialysis buﬀer. Experiments were
carried out at 22C and involved 30 successive 10 ml injec-
tions of 1mM peptide solution into a sample cell contain-
ing 100 mM protein solution. Heats of dilution were
subtracted and binding isotherms were plotted and
analysed with MicroCal Origin version 7.0, assuming a
single-site binding model.
Crystallization and structure determination of the
aprataxin FHA domain
Aprataxin FHA domain was crystallized by hanging-drop
vapour diﬀusion. Protein at a concentration of
10mg/ml in 50mM HEPES pH 7.5, 150mM NaCl,
5mM b-mercaptoethanol was mixed with an equal
volume of reservoir solution [0.2M ammonium ﬂuoride,
20% (w/v) PEG 3350] and incubated at 18C. Thin plates
grew within 1 week and were transferred into cryo-
protectant (0.1M ammonium ﬂuoride, 10 % PEG 3350,
25mM HEPES pH 7.5, 75mM NaCl, 25% PEG 400) and
ﬂash frozen in liquid nitrogen. Data were collected at
100K on an Raxis-IV detector mounted on a Rigaku
MicroMax-007HF rotating anode X-ray source, and
integrated and scaled using DENZO and SCALEPACK
(38). The structure was solved by molecular replacement
using the coordinates of PDB entry 1YJM as a search
model with AmoRe (39,40). Subsequent reﬁnement was
carried out at 1.65 A˚ using REFMAC5 (41) and manual
model building in Coot (42). Data collection and reﬁne-
ment statistics are summarized in Supplementary
Table S2. All structure ﬁgures were prepared with
PyMol (http://www.pymol.org). Coordinates have been
deposited in the Protein Databank: Accession code 3KT9.
High LET heavy ion irradiation procedure
For heavy ion irradiation experiments, cells were seeded on
sterilized glass coverslips and irradiated at the UNILAC
beamline at GSI (Darmstadt, Germany) with high energy
xenon ions (4.5 MeV/nucleon; LET 8815 keV/mm),
krypton (5.4 MeV/nucleon; LET 5060 keV/mm), nickel
(6.0 MeV/nucleon; LET 3430 keV/mm) or uranium ions
(4.2 MeV/nucleon; LET 14925 keV/mm), respectively.
Diﬀerent heavy ion species were used for the recruitment
studies since these experiments were carried out over
several years and we have had to adhere to the schedule
of radiation exposure at the Darmstadt GSI site in
Germany. Directly before the irradiation, the coverslips
were mounted into sample holders and placed in a
medium ﬁlled tank. For the ion irradiation, the sample
holders were automatically taken from the medium
tank, exposed to the ion beam under a small angle of 15
between the axis of the ion beam and the plane of the cell
monolayer and placed back again. For the applied ﬂuence
of 3 106 p/cm2, the whole procedure takes <30 s.
Immunoﬂuorescence and microscopy
For immunostaining, cells grown on coverslips were
washed with PBS, ﬁxed in 2% formaladehyde/PBS for
20min and permeabilized with PT-5 solution [PBS/0.5%
Triton X-100] for 5min. Non-speciﬁc binding was blocked
by incubating with PTB-5 [PBS/0.5% BSA] for 20min at
room temperature. Coverslips were then incubated with
mouse anti-gH2AX antibody (Upstate 1/500 in PTB-5)
for 1 h at room temperature. Cells were stained with
5 mg/ml Alexa 568 goat anti-mouse F(ab)2 conjugate
(Invitrogen) and the DNA counterstained with 1 mM
ToPro3 (Invitrogen). Microscopy was performed on a
Leica TCS NT confocal scanner equipped with an
ArKr-Laser on the Leica DM IRBE inverted microscope
(lens: HCX PlanApo 63x oil/NA1.32). Images were
recorded as confocal stacks with optical sections separated
by about 0.3mm. Confocal images were displayed as
maximum projections and assembled in Adobe
Photoshop 7.0. Heavy ion irradiation procedure is
described in Supplementary Data.
In vivo real-time beamline microscopy and heavy ion
irradiation
Cells were transfected with Amaxa Nucleofection technol-
ogy (Amaxa, Koeln, Germany). Transfection of MEFs
was performed with Amaxa Nucleofector Kit VDP-1004
and protocol A-023 according to the manufacturer
instructions (Amaxa, Germany). Mdc1/ and Mdc1+/+
cells transiently transfected with GFP-aprataxin were
employed for real-time ﬂuorescence intensity measure-
ments. These cells were cultivated on polycarbonate foil
(18-mm diameter; 40-mm thickness) and irradiated at the
beamline microscope as described earlier (28).
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cH2AX foci repair kinetics
Analysis of gH2AX repair foci kinetics was performed as
described earlier (43) and is described in Experimental
Procedures in Supplementary Data.
Analysis of SSB repair
SSB were induced by exposing conﬂuent cells to low doses
of H2O2 (50100 mM) in RPMI 1640 medium without
supplements for 15min at 37C. To remove H2O2, cells
were washed two times with PBSCMF (140mM NaCl,
3mM KCl, 8mM Na2HPO4 and 1mM KH2PO4). The
numbers of SSB were determined by an alkaline elution
assay as described earlier (44). The numbers of SSB in
untreated control cells were subtracted in all cases.
RESULTS
Recruitment of aprataxin to DNA damage and
co-localization with MDC1 after high LET
radiation exposure
A hallmark of DNA repair proteins is their capacity to
re-localize in discrete aggregates or foci within the nucleus
after DNA damage exposure. We have previously shown
that GFP-aprataxin co-localized with XRCC1 along
charged particle tracks (8). Irradiation of cells with
heavy ions generates multiple damaged sites including
DNA lesions like SSB, DSB and base modiﬁcations (45).
Here, we have focused on sites of DSB that can be
identiﬁed by the phosphorylation of histone H2AX
(gH2AX), the earliest detectable marker for DSB (22)
and by recruitment of MDC1 (30). To determine the
requirements for aprataxin recruitment to complex DNA
damage, cells were transfected with GFP-tagged
aprataxin, subjected to heavy ion irradiation at a small
angle (<15) from the horizontal and analysed by
confocal ﬂuorescence microscopy (Figure 1A). Expression
and localization of GFP-aprataxin and GFP-MDC1 in
unirradiated cells is shown in Supplementary Figure S1.
High LET heavy ion irradiation at low speciﬁc energies
produced discrete gH2AX aggregates/foci deposited along
the particle trajectory (Figure 1B) as observed earlier (46).
GFP-aprataxin was recruited to these sites of DSB as
observed by the partial co-localization pattern between
GFP-aprataxin and gH2AX (Figure 1B). To further
conﬁrm the recruitment of GFP-aprataxin to sites of
Figure 1. Co-localization of aprataxin with gH2AX and MDC1 at sites of DSB. (A) Methodology employed to study the dynamic recruitment of
GFP-tagged fusion proteins (aprataxin and MDC1) to localized DNA damage induced by heavy ion irradiation. Transfection of GFP constructs and
irradiation procedures are described in Supplementary Data. (B) Recruitment of GFP-aprataxin to uranium (4.2 MeV/nucleon LET 14925 keV/mm)
ions-induced DNA DSB in HeLa cells. DSB are visualized by gH2AX immunostaining and nuclei by ToPro3 staining. (C) Co-localization of
GFP-aprataxin with MDC1 along particle tracks after uranium ions irradiation in HeLa cells. (D) Recruitment of endogenous aprataxin to DSB and
co-localization with MDC1 along particle tracks after krypton ions irradiation (5.4 MeV/nucleon; LET 5060 keV/mm) revealed by immunostaining
with anti-aprataxin and anti-MDC1 antibodies in human ﬁbroblasts.
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DSB, we demonstrated co-immunostaining with MDC1
(Figure 1C), another DNA damage response factor that
is recruited to DSB through binding to gH2AX (34).
As was the case with gH2AX, co-localization was incom-
plete between aprataxin and MDC1 (Figure 1C). To con-
ﬁrm the recruitment of MDC1 to high LET heavy
ion-induced DSB, we used a GFP-MDC1 fusion protein.
As expected, GFP-MDC1 completely co-localized with
gH2AX staining at sites of heavy ion-induced DSB
(Supplementary Figure S2). To address possible artefacts
due to either overexpression or the presence of a GFP
tag attached to the N-terminus of aprataxin, immuno-
staining for endogenous aprataxin was also performed
(Figure 1D). In this case also, endogenous aprataxin was
recruited to sites of DSB as observed by partial
co-localization with MDC1 along the particle tracks. To
determine whether MDC1 mediates the recruitment of
aprataxin to sites of DNA DSB, wild-type and Mdc1/
MEFs were transiently transfected with GFP-aprataxin
and analysed for protein track formation after heavy
ion exposure. While aprataxin was recruited to DNA
breaks in wild-type MEFs after heavy ion irradiation
at 10min post-irradiation (4.5 MeV/nucleon; LET
8815 keV/mm), no recruitment was observed in Mdc1/
cells despite the formation of gH2AX tracks (Supple-
mentary Figure S3A). Due to poor transfection eﬃciency
of Mdc1 MEFs, the absence of aprataxin recruitment was
only observed in a limited number of cells. Accordingly, to
monitor the recruitment of aprataxin in MDC1-deﬁcient
cells over shorter time points (up to 4min), we employed
a remote-controlled system coupled to a beamline micro-
scope that allows measurement of GFP ﬂuorescence inten-
sity at sites of DNA breaks in real-time during heavy ion
irradiation (28). Both wild-type and Mdc1/ MEFs were
transiently transfected with GFP-aprataxin and subjected
to high LET heavy ion irradiation as described earlier
(28). Real-time imaging of GFP ﬂuorescence revealed
fast recruitment of aprataxin to sites of DNA damage
within 1min after irradiation in both Mdc1/ and wild-
type cells (Supplementary Figure S3B). Interestingly,
ﬂuorescence intensity at the sites of DNA damage drops
out rapidly inMdc1/ compared with wild-type cells sug-
gesting an increased rate of dissociation of GFP-aprataxin
from sites of DNA DSB in these cells. This indicates that
while MDC1 is not necessary for the initial recruitment
of aprataxin to sites of DNA DSB, its absence aﬀects the
retention of aprataxin to these sites. On the other hand,
loss of XRCC1 prevented any recruitment of aprataxin in
cells exposed to high LET radiation (Supplementary
Figure S4). Together, these results provide evidence that
aprataxin localizes at least in part to sites of DNA DSB,
and that MDC1 does not act to recruit aprataxin, but
rather as part of a tethering platform for aprataxin and
possibly other repair proteins, to ensure eﬀective DNA
DSB repair.
Interaction between aprataxin and MDC1
The co-localization of MDC1 and aprataxin to sites of
DNA breaks prompted us to determine whether these
two molecules associate. Using a combination of co-IP
and GST pull-down assays we demonstrated an inter-
action between endogenous aprataxin and MDC1.
MDC1 co-immunoprecipitated with aprataxin using a
speciﬁc anti-aprataxin antibody while non-speciﬁc serum
(Ig) failed to immunoprecipitate MDC1 (Figure 2A).
Three discrete MDC1 bands were detected as has been
reported earlier (30,34). This interaction was conﬁrmed
in a reverse co-IP with an anti-MDC1 antibody
(Figure 2B). To further characterize the interaction
Figure 2. Direct interaction between aprataxin and MDC1. (A) Co-IP
of MDC1 and aprataxin using an anti-aprataxin antibody followed by
immunoblotting with the respective antibodies. Non-speciﬁc serum (Ig)
is used as a negative control and the amounts of protein in WCE are
shown. (B) Co-IP of aprataxin with an anti-MDC1 antibody. Non-
speciﬁc serum (Ig) is included and WCE is also shown. (C) Diagram
of aprataxin domains and GST-fragments used in the pull-down assays.
(D) Protein extracts from control LCL (C3ABR) were either incubated
with GST alone or GST-aprataxin fragments. Bound proteins were
separated on SDS–PAGE and detected by anti-MDC1 antibodies.
Coomassie staining shows equivalent loading of GSTs. (E) Direct
binding of aprataxin to MDC1. Aprataxin FHA pull downs in
the absence or presence of BenzonaseTM, a potent nuclease that
degrades both RNA and DNA.
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between aprataxin and MDC1 and to map the interaction
domain on aprataxin, we performed aprataxin GST
pull-downs. Using a series of overlapping GST fusion
proteins, encompassing aprataxin FHA, HIT and zinc
ﬁnger domains (Figure 2C), we identiﬁed the N-terminal
region (amino acid 1110) of aprataxin as the MDC1
interaction domain (Figure 2D). Binding of MDC1 to
the aprataxin FHA domain was retained in the presence of
BenzonaseTM suggesting that this was not due to bridging
with nucleic acid but rather a direct proteinprotein inter-
action (Figure 2E). To conﬁrm the direct interaction
between aprataxin and MDC1, aprataxin GST pull
downs were carried out in the presence of ethidium
bromide (EtBr) (Supplementary Figure S5). EtBr did not
disrupt the interaction between the two proteins. On the
contrary, an increase in MDC1 binding was observed in
the presence of EtBr which may reﬂect an increase in
available soluble MDC1. Thus the co-localization of
aprataxin and MDC1 to sites of DNA damage induced
by high LET radiation is supported by evidence of a direct
interaction between these two proteins.
CK2 phosphorylation-dependent interaction of MDC1 with
the aprataxin FHA domain
FHA domains are conserved sequences of 65–150 amino
acid residues found principally within eukaryotic nuclear
proteins that have been shown to mediate phospho-
speciﬁc protein–protein interactions by binding to
phosphopeptides (47,48). Previous reports have demon-
strated that the interaction between aprataxin and
XRCC1 was dependent on phosphorylation of XRCC1
by CK2 (9,10). Furthermore, XRCC4 which is involved
in the repair of DNA DSB via the non-homologous end
joining pathway was also shown to bind to the FHA
domain of aprataxin (9). To determine whether XRCC4
could also target aprataxin to DNA breaks, we examined
the recruitment of aprataxin in Xrcc4/ cells. Normal
recruitment of GFP-aprataxin was observed in Xrcc4/
cells indicating that XRCC4, albeit binding to the FHA
domain of aprataxin, is not involved in its targeting to
heavy ion-induced DNA breaks (data not shown).
Nevertheless, the interaction between aprataxin and
XRCC4 may be important for the assembly of the
rejoining complex and/or to ensure eﬀective DNA end
‘clean-up’ during the repair process.
To determine whether the interaction between MDC1
and aprataxin is also dependent on phosphorylation of
MDC1, GST pull downs with the aprataxin FHA
domain were performed in the presence of protein phos-
phatase (Figure 3A and B). Alkaline phosphatase treat-
ment disrupted the binding of MDC1 to the aprataxin
FHA domain demonstrating a phosphorylation-
dependent interaction between the two proteins
(Figure 3B). Since CK2 was found to phosphorylate
XRCC1 to mediate the aprataxin–XRCC1 interaction
(9,10), we therefore investigated whether CK2 could also
phosphorylate MDC1 and thus mediate the interaction
between the two proteins. As shown in Figure 3C, inhibi-
tion of CK2 activity in vivo with increasing concentration
of the speciﬁc CK2 inhibitor, 4,5,6,7-Tetrabromotriazole
(TBB), resulted in decreased binding of MDC1 to the
aprataxin FHA domain. Use of another CK2-speciﬁc
inhibitor, 2-dimethylamino-4,5,6,7-tetrabromo-1H-
benzimidazole (DMAT), also showed a reduction in
MDC1 binding to aprataxin FHA (Supplementary
Figure S6). Analysis of MDC1 protein sequence using
GPS2.0 TM, NetPhos2.0TM, ScansiteTM prediction
programs and cross-reference with the Phospho-ELMTM
database identiﬁed several putative CK2 phosphoryla-
tion sites within the N-terminal region of MDC1
(Supplementary Figure S7). To conﬁrm the CK2
phosphorylation-dependent interaction between aprataxin
and MDC1, we made a GST fusion protein corresponding
to the N-terminal region of MDC1 residues (150–350)
that contains nine potential sites for CK2, three of
which are predicted to be pT and required for FHA
binding. The GST-fusion protein (150–350) was in vitro
phosphorylated with recombinant human CK2 and pull
downs were performed. As shown in Figure 3D, MDC1
fragment 150–350 pulled down endogenous aprataxin
from total cell extracts (Figure 3D, Lane 4) after in vitro
Figure 3. CK2-mediated phosphorylation-dependent binding of MDC1
to the aprataxin FHA domain. (A) Diagram of aprataxin GST fusion
used in the pull-down assays. (B) Eﬀect of protein phosphatase activity
on MDC1 binding to the aprataxin FHA domain. Whole cell extracts
from HeLa cells were mock treated or treated with alkaline phos-
phatase (Alk PPase: 2500 U) for 1 h at room temperature and subse-
quently used for pull-down assays using GST only, and GST-aprataxin
FHA domain. (C) Reduced binding of MDC1 to the aprataxin FHA
domain following CK2 inhibitor treatment. HeLa cells were treated for
8 h with increasing concentrations of CK2 inhibitor TBB, lysed and
WCE were used for GST pull-down assays. (D) Schematic of MDC1
protein sequence showing the GST fusion protein (150–350) used in the
pull-down assays. In vitro binding of CK2-phosphorylated (150–350)
region of MDC1 with HeLa WCE. Binding endogenous aprataxin to
CK2-phosphorylated MDC1 (150–350) fragment was revealed by
immunoblotting.
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CK2 phosphorylation, indicating that the CK2-
phosphorylated 150–350 region is the aprataxin binding
domain on MDC1.
Binding of aprataxin to CK2-phosphorylated MDC1
pSDpTD sites
To conﬁrm and quantify the interaction between the
aprataxin FHA domain and CK2-phosphorylated
MDC1, binding experiments were performed by ITC
using recombinant aprataxin FHA domain and
phosphorylated MDC1 peptides. FHA domains typically
target pT residues (47,48), and within the ﬁrst 500 residues
of MDC1 there are seven threonine residues found in
putative CK2 phosphorylation sites. Six of these are
present in highly conserved sequences with the consensus
D/N-S-D-T-D-x-E/D-E/D-E/D with additional prefer-
ences for small hydrophobic residues (Ala/Val) in the pT
+2 position, and medium hydrophobic residues (Leu/Ile)
in the pT4 site (Figure 4A and Supplementary Figure
S7). Whilst the threonine sites are predicted to be the best
CK2 substrates, the preceding serines (S) are also putative
phosphorylation sites for CK2. Therefore, both mono-
and di-phosphorylated peptides were tested in ITC exper-
iments (Figure 4B and C and Supplementary Table S1).
A 14-residue peptide encompassing S329 and T331 was
chosen, as these residues have been detected in the
phosphorylated form of MDC1 in vivo (49–52). As
shown in Figure 4B, the peptide phosphorylated only on
T331 bound the aprataxin FHA domain stoichiome-
trically, albeit with an aﬃnity of 58 mM. However, intro-
duction of a second phosphate on residue S329 increased
binding aﬃnity 10-fold to 5.6mM (Figure 4C) which is
well within the range of binding aﬃnities previously
observed for FHA domains in other signalling contexts
and similar to the 4.1mM aﬃnity observed by ITC for
binding of polynucleotide kinase (PNK) FHA to CK2-
phosphorylated XRCC4 (53). Importantly, no detectable
binding to peptides phosphorylated only on S329 was
observed even at high concentration in the ITC experi-
ment (Figure 4B), demonstrating an absolute dependence
of binding on threonine phosphorylation. A shorter
di-phosphorylated peptide, terminating after the pT+3
position, bound aprataxin with comparable aﬃnity to
the longer version, possibly echoing the unusual lack of
sequence selectivity in residues C-terminal to the pT
observed by in vitro library screening of the PNK FHA
domain (53; Supplementary Table S1). Thus, these data
clearly demonstrate that aprataxin binds to a conﬁrmed
CK2 phosphorylation site in MDC1 in a pT-dependent
fashion, its aﬃnity is signiﬁcantly elevated in the
di-phospho form and supports the MDC1/aprataxin inter-
action data described in Figure 3. To substantiate ITC
binding data, aprataxin GST pull downs were performed
using GFP-MDC1 mutant constructs (Figure 4E).
Wild-type (SDTD) MDC1 sequence, a mutant where the
SDTD region was deleted (SDTD), and a mutant where
the key Thr residue was changed to Ala (SDAD)2 were
expressed in HeLa cells and GST pull downs using
aprataxin FHA domain were carried out. As expected,
wild-type MDC1 was eﬃciently pulled down, while both
the (SDTD) and (SDAD)2 were not (Figure 4F).
Together, these data suggest that the aprataxin FHA is
able to detect varying phosphorylation levels that
directly modulate its aﬃnity for MDC1. Given the simi-
larity in sequences, it seems highly likely that the aprataxin
FHA domain can bind to any of the six sequences in
MDC1 that contain the core SDTD motif. Since both
aprataxin and Nbs1 bind to the same
CK2-phosphorylated region of MDC1 (51,52,54), we
determined whether Nbs1 could be in a complex with
aprataxin and MDC1, and whether it was required for
the recruitment of aprataxin to sites of DNA damage.
Using Nbs1 defective cells, we demonstrate that both
aprataxin binding to MDC1 and its recruitment to
DNA breaks was independent of Nbs1 (Supplementary
Figure S8). Thus, this suggests that MDC1 interacts
with multiple proteins through a common CK2-
phosphorylated region, and that it may reside in several
distinct protein complexes within the cell. The presence of
multiple phosphorylated SDTD motifs would provide a
high local concentration of binding sites for aprataxin,
Nbs1 and, potentially, other pS/T-dependent binding
proteins.
Structure of the aprataxin FHA domain and a model
for pSDpTD interactions
To further investigate the molecular basis of the
phosphopeptide aprataxin FHA interaction, we attempted
to crystallize the aprataxin FHA domain both with
and without bound phosphopeptide. The apo protein
crystallized readily and the structure was determined by
molecular replacement using PNK FHA domain as the
search model (1YJM). Residues 1–102 of the aprataxin
FHA domain were modelled into the density and the
structure was reﬁned to an Rfree value of 23.7% at
1.65A˚, with excellent stereochemistry (Supplementary
Table S2). As expected the aprataxin FHA domain is
structurally similar to that of PNK, with which it shares
39% sequence identity, and both adopt the classical FHA
b-sandwich topology. The two structures superimpose
with an overall root mean-square deviation in alpha
carbon atoms of 0.6 A˚ for a core of 82 matched Ca’s,
with largest deviations occurring in the loops connecting
b1–b2 and b6–b7 (Figure 5A), consistent with the pattern
of sequence conservation (Figure 5B). Despite extensive
screening, the aprataxin FHA domain has, thus far,
failed to crystallize in complex with either the mono- or
di-phosphorylated MDC1 peptide. However, although the
PNK and aprataxin FHA domains have only 39%
sequence identity, they do show a remarkably high struc-
tural conservation at and around the phosphopeptide
binding site. We were, therefore, able to model the
pSDpTD peptide into the apo structure, using the PNK
FHA domain structure with an XRCC4 phosphopeptide
bound as a guide (55; Figure 5C). As has been observed in
all previously characterized FHA–phosphopeptide inter-
actions, pT recognition is provided by Arg29 and Ser41
(equivalent to PNK Arg35 and Ser47).
The weakly conserved isoleucine at the pT4 position
of the MDC1 peptide is in contact with Pro31, which is
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Figure 4. Aprataxin binds to a conserved di-phosphorylated CK2 motif in MDC1. (A) MDC1 contains six conserved motifs with a core SDTD
motif that is di-phosphorylated in vivo (48–50). (B) ITC binding isotherms for interaction of wild-type aprataxin FHA with pSDTD and SDpTD
phosphopeptides (C, D) ITC binding isotherms for the titration of pSDpTD phosphopeptide into wild-type and K38A aprataxin FHA, respectively.
(E) Diagram of GFP-MDC1 mutants used in the pull-down assays. (F) Aprataxin FHA GST pull downs from HeLa cells expressing wild-type
GFP-MDC1, a mutant containing a deletion of the SDTD region (SDTD), and a mutant where the Thr residues contained in the SDTD sequence
were replaced by Ala (SDAD)2.
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conserved in PNK FHA and which forms a platform for
interaction with a pT4 tyrosine in the PNK/XRCC4
complex (55). Arg42 (PNK Arg48) occupies a position
that is weakly conserved in the FHA domain family,
and is suitably positioned for pT interaction. Most
importantly, the model suggests that selectivity for pS in
the pT–2 position is provided by a basic surface created
by Arg29 and Lys38. In support of this, mutation of
Arg44 in PNK, which is structurally equivalent to
aprataxin Lys38, abolishes PNK binding to XRCC4
phosphopeptides containing a glutamate rather than pS
at the –2 position (55). To test this hypothesis ITC exper-
iments were repeated with Arg29Ala (R29A) and
Lys38Ala (K38A) mutant FHA domains. Consonant
with its highly conserved role in pT interactions in all
FHA domains, the R29A mutant reduced binding to the
di-phosphorylated MDC1 peptide to undetectable levels.
For K38A, both the monothreonine phosphorylated and
di-phosphorylated peptides bind to the mutant with
aﬃnities comparable to that observed for wild-type
FHA interaction with the monothreonine phosphorylated
ligand (Figure 4D and Supplementary Table S1). Thus,
substitution of Lys38 eﬀectively eliminates the addi-
tional binding aﬃnity provided by accessory serine
phosphorylation, consistent with our structural model.
Overall, the functional signiﬁcance of the extended
binding surface evident from these experiments is
exempliﬁed by the fact that Lys38, Lys39, Arg29 and
Arg42 constitute four of only ﬁve basic residues conserved
in PNK from a total of 15 present in the aprataxin FHA
(Figure 5B).
Aprataxin FHA Arg29Ala mutant ablates the
phospho-dependent aprataxin–MDC1 interaction
ITC data using puriﬁed aprataxin FHA and synthetic
peptides, together with the crystallographic structure of
aprataxin FHA and in silico modelling of MDC1
peptide binding demonstrated the importance of basic
residues which include Arg29 and Lys38 for the binding
of di-phosphorylated MDC1 peptide. To conﬁrm these
Figure 5. Structural comparison of the aprataxin and PNK FHA domains and modelling of the aprataxin–MDC1 interaction. (A) Superposition of
Ca backbone structures of the aprataxin FHA domain (green) with that of the PNK FHA/XRCC4 phosphopeptide complex (grey). (B) Sequence
alignment of the core FHA domains residues from aprataxin and PNK. Identical positions are shown in red with the highly conserved arginine and
serine residues that make canonical pT contacts in all available FHA-phosphopeptide structures are boxed. Black dots highlight the ﬁve Arg/Lys
residues conserved between the two proteins. (C) Modelling of the aprataxin FHA–pSDpTD MDC1 phospho-motif complex (left) based on the
crystal structure of the aprataxin FHA domain and the PNK–XRCC4 complex structure (right).
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data, aprataxin GST pull downs using both Arg29Ala
(R29A) and Lys38Ala (K38A) mutants were performed
with total cell extracts. While MDC1 bound to the
wild-type FHA sequence, R29A FHA mutant ablated
MDC1 binding (Figure 6A), in agreement with the ITC
binding and modelling data. Similarly, substitution of
Lys38 eﬀectively eliminates the additional binding
aﬃnity provided by accessory serine phosphorylation
(Figure 4D) and, consistent with the extremely low
aﬃnity (80 mM), GST pull downs with the K38A FHA
mutant also did not show any signiﬁcant interaction with
MDC1 (Figure 6A).
Recruitment of aprataxin to sites of DNA damage is
abolished by Arg29Ala mutation
To investigate the functional importance of the aprataxin
FHA domain as a protein–protein interaction platform
and its potential role in targeting aprataxin to DNA
damage, we examined the eﬀect of Arg29Ala and
Lys38Ala FHA mutations on the in vivo recruitment of
aprataxin to sites of DNA breaks. Recruitment of
aprataxin to heavy ion-induced DNA damage was
visualized using GFP-aprataxin containing either the
wild-type sequence, R29A or K38A substitutions.
GFP-aprataxin carrying the wild-type sequence was eﬀec-
tively recruited to DNA breaks as demonstrated by the
co-localization with gH2AX along the particle tracks
(Figure 6B) and as previously shown in Figure 1.
Consistent with the ITC experiments, no recruitment to
sites of DNA damage was observed with the R29A FHA
mutant, while recruitment was reduced in the K38A
aprataxin mutant (Figure 6B). Similar results were
obtained with laser irradiation (data not shown). These
data demonstrate the importance of the FHA domain in
mediating phosphorylation-dependent protein–protein
interactions and in targeting aprataxin to sites of DNA
breaks.
Normal repair of IR-induced DSB in aprataxin-deﬁcient
cells
The interaction between aprataxin, XRCC4 and MDC1
and its recruitment to heavy ion irradiation-induced DNA
damage suggest a role for aprataxin in the repair of DSB.
To get further insight on the functional relevance of
aprataxin recruitment to DNA breaks and its interaction
with MDC1, we transfected both wild-type and FHA
R29A mutant full length APTX cDNAs in AOA1
(FD105) ﬁbroblasts and measured the repair kinetics of
DSB in these cells. Repair of DSB was monitored by
imaging the disappearance of gH2AX foci, a surrogate
marker for DSB formation and rejoining, after low LET
IR. Similar DSB repair kinetics were observed in AOA1
and AOA1 complemented with wild-type GFP-aprataxin,
indicating that aprataxin is not necessary for the repair of
DSB induced by low LET irradiation (Figure 7A). AOA1
cells transfected with GFP-aprataxin R29A exhibited a
similar DSB repair kinetic (Figure 7A). While aprataxin
has been implicated in DSB processing through its inter-
action with XRCC4, and the interaction with MDC1
described here, we failed to detect any signiﬁcant diﬀer-
ence in the repair kinetics of low LET-induced DSB in the
presence or absence of aprataxin. Similar results were
obtained for H2O2-induced DSB (Supplementary Figure
S9). While surprising to some extent, these data are in
agreement with previous reports which failed to detect a
signiﬁcant DSB repair defect in AOA1 after IR and H2O2
treatments (9,19). Not surprisingly, Mdc1/ cells display
some defect in the repair of DNA DSB induced by low
LET IR (Figure 7B). These data are in agreement with the
reported role of MDC1 in the signalling and repair of
IR-induced DNA DSB (30–34,56). While high LET
heavy ion radiation, IR and H2O2 are all capable of
inducing DSB, they also induce a variety of DNA
lesions that include base damage and SSB (45).
Although MDC1 has been solely implicated in DSB rec-
ognition and repair, the induction of SSB by high LET
heavy ion radiation prompted us to investigate whether
Figure 6. Key role of aprataxin FHA domain in targeting aprataxin to
sites of DNA damage in vivo. (A) Substitution of Arg29 and Lys38 to
Ala abrogated the interaction between aprataxin and MDC1 as deter-
mined by pull-down assays as described earlier. (B) Eﬀect of Arg29Ala
and Lys38Ala mutations on the recruitment of aprataxin to high LET
heavy ion-induced DSB in HeLa cells. HeLa cells were transiently
transfected with wild-type GFP-aprataxin, GFP-aprataxin R29A or
GFP-aprataxin K38A mutants, and cells were subjected to nickel ions
irradiation (6.0 MeV/nucleon; LET 3430 keV/mm). DSB are visualized
by gH2AX immunostaining and nuclei by ToPro3 staining.
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MDC1 may also participate in SSB repair. In contrast to
Aptx/ cells where there is evidence for a defect in the
repair of DNA SSB, normal SSB repair was observed in
Mdc1/ cells (Supplementary Figure S10), indicating that
MDC1 is not required for the repair of SSB, and that the
interaction described here between aprataxin and MDC1
may only be relevant to a subset of DSB, those resulting
from abortive DNA ligation attempts.
DISCUSSION
Previous reports have shown that aprataxin interacts with
XRCC1, Ligase III and PARP-1, implicating it in the
repair of SSB (8–10). Further evidence for its role in
repair of single strand interruptions in DNA was
provided by Ahel et al. (2006) who showed that it
resolves abortive DNA ligation intermediates. We have
provided additional evidence here for a defect in SSB
repair in AOA1 cells after exposure to H2O2 which
supports the speciﬁc role of aprataxin in repairing only a
subgroup of relatively ‘slowly processed’ SSB carrying
abortive ligation intermediates, since the reduced rate of
repair in Aptx/ cells is only signiﬁcant at later time
points (>15min). Importantly, a delay in the repair of
DNA SSB was only detected in non-proliferating cells,
consistent with the results of Reynolds et al. (2009)
where a defect in SSB repair was observed in AOA1
cells after inhibiting proliferation with aphidicolin (57).
These data are in agreement with the SSB repair delay
observed in AOA1 ﬁbroblasts caused by intracellular
accumulation of reactive oxygen species, where this
repair defect was also evident after 1 h post-treatment
(12). Notwithstanding these observations there exists
some disagreement in the literature on the capacity of
AOA1 cells to repair SSB (9,19). This may be explained
by the speciﬁc mutation in AOA1, the cell type used
(proliferating versus non-proliferating) or the repair
assay, alkaline comet versus the alkaline elution assay.
More recently, Reynolds et al. (2009) demonstrated that
short-patch SSB repair in AOA1 cell extracts bypasses the
point of aprataxin action at oxidative breaks, resulting in
the accumulation of adenylated DNA nicks. This defect
results from insuﬃcient levels of non-adenylated DNA
ligase, and short-patch SSB repair could be restored
in AOA1 extracts by the addition of recombinant DNA
ligase (57). In addition, aphidicolin inhibition of
long-patch repair uncovered a signiﬁcant defect in SSB
repair in Aptx/ neural astrocytes while it did not aﬀect
SSB repair rates in wild-type mouse neural astrocytes (57).
Most recently, Harris et al. (2009) provided evidence
for reduced expression of key base excision repair
proteins (PARP-1, APE1 and OGG1) in AOA1 cells,
and revealed the presence of elevated levels of oxidative
DNA damage in these cells coupled with reduced base
excision and gap ﬁlling repair eﬃciencies (17). Thus, a
synergy between aprataxin, PARP-1, APE-1 and OGG1
in the DNA damage response uncovered both direct and
indirect modulating functions for aprataxin in base
excision repair (17). In addition, we also have shown
here that aprataxin was not recruited to DNA breaks in
the absence of XRCC1. Together, these data demonstrate
that aprataxin participates in chromosomal SSB repair in
vivo, that it modulates base excision repair eﬃciency and
suggest that short-patch SSB repair is arrested in AOA1
because of insuﬃcient non-adenylated DNA ligase.
Clements et al. (2004) identiﬁed XRCC4 as a binding
partner for aprataxin using a yeast 2-hybrid screen and
conﬁrmed this by demonstrating co-IP with DNA ligase
IV, a constitutive binding partner. Since XRCC4/Ligase
IV is an essential component of the non-homologous
end-joining (NHEJ) pathway these data suggested that
aprataxin might also be involved in proof-reading or
processing of DSB. We provide here compelling evidence
that aprataxin is recruited to sites of DNA damage and
interacts with MDC1, an important component of the
DNA damage response. MDC1 is required for eﬃcient
phosphorylation of H2AX, for recruitment and retention
of ATM and MRN adjacent to break sites (29,30,34,35)
and for the recruitment of the ubiquitin ligase RNF8 to
ubiquitinate H2AX at damaged sites (58–61). This protein
appears to act as a scaﬀold to bring together several DNA
Figure 7. Normal repair of IR-induced DSB in AOA1 cells.
(A) gH2AX foci repair kinetic after low LET ionizing radiation
(IR; 2Gy). AOA1 ﬁbroblasts (FD105) were transfected with either
GFP-aprataxin (wild-type) or GFP-aprataxin (R29A) mutant. Untrans-
fected cells were used as control. Graph represents average numbers
of foci per cell SD. Foci were counted in 50–60 individual cells per
time point. DSB repair kinetics were similar regardless of the presence
of absence of aprataxin indicating that aprataxin is not required
for low LET IR-induced DSB repair. (B) Repair kinetics of DSB
(gH2AX foci) after low LET irradiation (IR) in wild-type and
Mdc1/ cells. Graph represents average number of foci per cell SD.
Foci were counted in 50–60 individual cells per time points a signiﬁcant
diﬀerence was observed at 6 and 8 h post-irradiation (*P< 0.05,
Student’s t-test).
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damage response proteins to mediate and enhance the
recognition and signalling of DSB (58–66). Our data add
an additional DNA repair protein, aprataxin, to the list of
proteins interacting with MDC1. MDC1 interacts with
DNA damage response proteins in a number of diﬀerent
ways. Interaction with gH2AX and the anaphase-
promoting complex occurs through its C-terminal,
BRCT domain (33,34,65), while it binds DNA-PK
through an internal set of repeat sequences (32). It also
possesses an FHA domain (amino acids 55–124) that
mediates interaction with Chk2 and Rad51 (33,66).
It employs an S/TQ rich region for ATM-dependent inter-
action with the ubiquitin ligase RNF8 (58).
We have described here a novel interaction between
MDC1 and aprataxin, involving an extended cluster of
CK2 phosphorylation sites (S-D-T-D) located down-
stream from the MDC1 FHA domain (amino acids
150–350). This was conﬁrmed by the use of CK2 inhibi-
tors, binding studies after in vitro CK2 phosphorylation,
GST pull downs and modelling studies based on binding
of mono- and di-phosphorylated peptides to the aprataxin
FHA domain and the X-ray crystal structure of this
domain. We provide here compelling evidence for a role
for CK2 activity in the interaction of this region of MDC1
with aprataxin and show that a phosphopeptide contain-
ing a core pSDpTD motif corresponding to one of these
sites binds to the FHA domain of aprataxin with high
aﬃnity. While a single threonine phosphorylation is
both necessary and suﬃcient for binding, aﬃnity is sub-
stantially increased by secondary serine phosphorylation.
This, in turn, appears to provide for accessory interactions
with an extended FHA phosphopeptide binding surface
not previously documented. The data presented here
uncover another important role for CK2 in mediating
the interaction between aprataxin and the DSB repair
protein MDC1.
In three recent reports constitutive phosphorylation of
the N-terminal SDT repeats of MDC1 by CK2 has been
demonstrated in the recruitment of the MRN complex to
sites of DSB through direct interactions with the FHA
domain of Nbs1 (51,52,54). Spycher et al. (54) reported
that doubly phosphorylated pSDpT motifs regulate the
accumulation and retention of the MRN complex in the
DSB-ﬂanking chromatin, and depletion of CK2 disrupted
the MDC1–MRN complex and DNA damage-induced
Nbs1 foci formation. Moreover, disruption of the SDT
phosphoacceptor sites on MDC1 prevented the
recruitment of Nbs1 to damaged chromatin (51,52,54).
We have demonstrated that Nbs1 is not required for
the binding of aprataxin to MDC1 and its recruitment
to sites of DNA damage. Therefore, MDC1 interacts
with multiple proteins through a common
CK2-phosphorylated region and may reside in several
distinct protein complexes within the cell. It is likely that
the interaction between MDC1/Nbs1 and MDC1/
aprataxin is inﬂuenced or regulated by the relative abun-
dance of these proteins in the cells. These data together
with previous ﬁndings that identiﬁed a direct role for CK2
in the repair of chromosomal DNA strand breaks (67), the
CK2-dependent aprataxin/XRCC1 (9,10) and aprataxin/
XRCC4 (9) interactions provide growing evidence for
a role for CK2 in maintaining genome integrity by
contributing to protein–protein complexes formation
and/or recruitment of DNA damage regulators/repair
factors at sites of DNA lesions.
As shown here, aprataxin re-localizes rapidly to discrete
foci along charged particle tracks that overlap with
gH2AX foci, a marker of DSB after exposure of cells to
high LET radiation which gives rise to complex damage
in DNA (22). The recruitment and co-localization of
aprataxin to sites of gH2AX-labelled DNA breaks has
previously been observed using diﬀerent heavy ion
species (8,17,28, this work). However, while MDC1
completely co-localized with gH2AX in the DSB-
ﬂanking microenvironment as reported earlier (68),
aprataxin only partially co-localized with MDC1 and
gH2AX in smaller foci (microfoci). This suggests that
aprataxin may be recruited only to the DSB or a
sub-group of DNA breaks directly within sites of
complex or clustered damage or that its association with
DNA damaged sites may be more transient. This transient
behaviour has been described for Nbs1 in the absence of
MDC1 (26,52). In addition, we provide evidence here that
the lack of MDC1 doesn’t aﬀect the rapid recruitment of
aprataxin to sites of high LET-induced DNA DSB, but in
contrast aﬀects the retention of aprataxin at sites of DNA
breaks, supporting a role for MDC1 as a scaﬀold during
the DNA damage response. Proteins such as SMC1 and
DNA-PKcs that are clearly involved in the DNA damage
response cannot be localized to sites of DNA damage
except after exposure to extremely high doses of radiation
(68). Spatial-co-localization studies revealed that unlike
gH2AX and MDC1, phosphorylated DNA-PKcs was
localized only at very speciﬁc regions, presumably repre-
senting sites of DSB within the tracks (69). The presence
of microfoci surrounded by regions of gH2AX-modiﬁed
chromatin after laser-induced DNA damage has been
reported (68). Several factors involved in DNA repair
including Nbs1 and Mre11 are present in microfoci
located in the centre of microirradiated tracks and sur-
rounded by vast regions of gH2AX-modiﬁed chromatin
(68,70). In the present context these microirradiated
tracks coincide with MDC1-modiﬁed chromatin. The het-
erogeneity of staining may be explained by the presence of
signiﬁcant amounts of ssDNA adjacent to DSB and/or the
presence of clustered or complex DNA damage (45,46).
Exposure of cells to low LET radiation (IR) or H2O2
failed to localize aprataxin to sites of damage (8). This
may be similar to that observed for SMC1 or DNA-PK
where extremely high levels of damage are required to see
such localization (68). Low LET radiation is more
sparsely ionizing and thus less damaging to DNA than
the complex forms of damage arising from high LET
exposure which could explain the failure to see aprataxin
foci after low LET radiation (45). The diﬀerence in
capacity of aprataxin to localize to sites of DNA
damage after the two types of IR correlates well with
the extent of repair of DNA DSB. The rate of repair of
DNA DSB in response to low LET radiation was unaf-
fected by aprataxin status of the cells. Similar to previous
reports (9,19), the failure to detect any signiﬁcant DSB
repair defect in the presence or absence of aprataxin
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after low LET irradiation or high doses of H2O2 suggests
that aprataxin recruitment to DNA breaks may only be
relevant for a sub-group of breaks, possibly
more frequently/eﬀectively induced by high energy and
high LET heavy ions irradiation. This sub-group of
breaks could represent those where abortive ligation was
occurring, a property of AOA1 cells (14).
The interaction of aprataxin with DNA damage recog-
nition and repair proteins suggest that aprataxin partici-
pates in the processing of some SSB and DSB to resolve
abortive DNA ligations. The model described in Figure 8
provides an integrated approach as to how aprataxin may
function at sites of damage (DSB and SSB) in DNA. This
involves recruitment to damaged sites by XRCC1, MDC1
and other unidentiﬁed factors, followed by interaction
with either XRCC1/LigaseIII or XRCC4/LigaseIV to
assist in the DNA end-processing and resealing of SSB
and DSB, respectively. In summary, it is likely that
aprataxin contributes to the repair of both DNA SSB
and DSB in its capacity to resolve abortive ligation inter-
mediates. This is most evident when cells are exposed to
agents that form complex damage in DNA.
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